Daniel K. Ludwig, who gave his entire fortune to cancer research, worked hard to ensure the world knew as little about him as possible. Learn where he came from, what he was like and how he built his sprawling conglomerate in this excerpt from a book we published on the history of Ludwig Cancer Research.
Read More
Ludwig Princeton researchers have discovered a metabolic quirk that tumor-infiltrating T lymphocytes (TILs) share with cancer cells, one that sets up a competition between the two. The researchers show in preclinical studies how this competition might be exploited through a simple dietary intervention to boost the efficacy of cancer immunotherapy.
Ludwig Lausanne researchers reported a mechanism by which the lipid prostaglandin E2 poisons the metabolism of tumor-targeting CD8+ T cells and showed in preclinical studies how it might be disrupted to improve responses to adoptive cell therapy employing tumor-infiltrating lymphocytes.
Read More
